Bioavailability enhancement services market to exhibit 11 percent CAGR
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
List view / Grid view
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
The first BTK inhibitor of any kind approved for mantle cell lymphoma treated with a covalent BTK inhibitor, has been granted FDA approval.
An innovation in hydrogels has created a portable, reusable chemical-producing platform that could provide access to essential pharmaceuticals without specialised storage requirements.
The rare brain infection, progressive multifocal leukoencephalopathy, in people with brain cancer could be treated using adoptive T-cell therapy...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects...